Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1753-1757

  Shinozaki, Masaru ^a   Fujimoto, Akihide ^a   Morton, Donald L ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAS PROTEIN;

ADULT; AGED; ARTICLE; B RAF ONCOGENE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; EXON; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MELANOMA; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA PRIMERS; DNA, NEOPLASM; EXONS; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 1842428668     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1169-3     Document Type: Article

References (21)

1. Clark, W. H. Tumour progression and the nature of cancer. Br. J. Cancer, 64: 631-644, 1991.
2. Ackerman, A. B., and Mihara, I. Dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome, and the relation between dysplastic nevi and malignant melanomas, Hum, Pathol., 16: 87-91, 1985.
3. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
4. Brose, M. S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn, E., Herlyn, M., Minna, J., Nicholson, A., Roth, J. A., Albelda, S. M., Davies, H., Cox, C., Brignell, G., Stephens, P., Futreal, P. A., Wooster, R., Stratton, M. R., and Weber, B. L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 62: 6997-7000, 2002.
5. Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., and Meltzer, P. S. High frequency of BRAF mutations in nevi. Nat. Genet., 33: 19-20, 2003.
6. Peyssonnaux, C., and Eychene, A, The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell, 93: 53-62, 2001.
7. Marais, R., Light, Y., Paterson, H. F., Mason, C. S., and Marshall, C. J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem., 272: 4378-4383, 1997.
8. Smalley, K. S. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int. J. Cancer, 104: 527-532, 2003.
9. Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., and Sidransky, D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. (Bethesda), 95: 625-627, 2003.
10. Yuen, S. T., Davies, H., Chan, T. L., Ho, J. W., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Tsui, W. W., Chan, A. S., Futreal, P. A., Stratton, M. R., Wooster, R., and Leung, S. Y. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res., 62: 6451-6455, 2002.
11. Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Van Belle, P., Elder, D. E., and Herlyn, M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res., 63: 756-759, 2003.
12. Hoon, D. S., Fujimoto, A., Shu, S., and Taback, B. Assessment of genetic heterogeneity in tumors using laser capture microdissection. Methods Enzymol., 356: 302-309, 2002.
13. Spugnardi, M., Tommasi, S., Dammann, R., Pfeifer, G. P., and Hoon, D. S. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res., 63: 1639-1643, 2003.
14. Morton, D. L., Hsueh, E. C., Essner, R., Foshag, L. J., O'Day, S. J., Bilchik, A., Gupta, R. K., Hoon, D. S., Ravindranath, M., Nizze, J. A., Gammon, G., Wanek, L. A., Wang, H. J., and Elashoff, R. M. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg., 236: 438-448, 2002.
15. Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C., and van den Oord, J. J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Investig. Dermatol., 117: 1483-1489, 2001.
16. Ball, N. J., Yohn, J. J., Morelli, J. G., Norris, D. A., Golitz, L. E., and Hoeffler, J. P. Ras mutations in human melanoma: a marker of malignant progression. J. Investig. Dermatol., 102: 285-290, 1994.
17. Lang, J., Boxer, M., and MacKie, R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum. Mutat., 21: 327-330, 2003.
18. Berwick, M., and Weinstock, M. Epidemiology: current trends. In: C. M. Balch, A. N. Houghton, A. J. Sober, and S-J. Soong (eds.), Cutaneous Melanoma, Ed. 4. St. Louis: Quality Medical Publishing, Inc., 2003.
19. Elder, D. E., Van Belle, P., Elenitsas, R., Halpern, A., and Guerry, D. Neoplastic progression and prognosis in melanoma. Semin. Cutan. Med. Surg., 15: 336-348, 1996.
20. Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Zonai Z., and Aaronson, S. A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res., 63: 3883-3885, 2003.
21. Zhu, J., Woods, D., McMahon, M., and Bishop, J. M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev., 12: 2997-3007, 1998.